Unleashing the power of digital pathology and AI for precision medicine
Posted 2nd October 2019 by Joshua Sewell
We’re looking back at the highlights from the Digital Pathology and AI meeting in 2018 as we anticipate this year’s Digital Pathology and AI Congress in December. This second post in our mini-series reviews Marylin Bui’s keynote presentation where she explained how the combination of Digital Pathology and Artificial Intelligence (AI) holds huge potential for patient care.
Flow Cytometry: A powerful tool in drug discovery
Posted 17th June 2019 by Joshua Sewell
Flow cytometry is a powerful tool in drug discovery because it provides a way to understand the drug’s mechanism of action. In order to stratify a better target for patients, you often need to know where the drug is working, and what kind of pathway it is operating along.
Using customer needs to drive Blockchain innovation
Posted 29th May 2019 by Joshua Sewell
Manuela Maria Schöner, part of the Corporate Strategy & Consulting division at Boehringer Ingelheim, spoke to us recently about her work with blockchain. She described her perspective on the use of data in the industry, and how Blockchain could become a key tool in meeting the needs of the primary stakeholders: patients.
Empowering patients: creating a healthcare data Blockchain network
Posted 26th April 2019 by Joshua Sewell
Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.
Assays in clinical trials and pharmacovigilance
Posted 27th January 2017 by Jane Williams
Assays are crucial during pre-clinical and clinical trials, and for pharmacovigilance. By this stage, the molecule has already been fully profiled with a mechanism of action, and efficacy and safety are now being assessed in vivo.